PE20141432A1 - Anticuerpos neutralizantes de citomegalovirus humano - Google Patents

Anticuerpos neutralizantes de citomegalovirus humano

Info

Publication number
PE20141432A1
PE20141432A1 PE2014000662A PE2014000662A PE20141432A1 PE 20141432 A1 PE20141432 A1 PE 20141432A1 PE 2014000662 A PE2014000662 A PE 2014000662A PE 2014000662 A PE2014000662 A PE 2014000662A PE 20141432 A1 PE20141432 A1 PE 20141432A1
Authority
PE
Peru
Prior art keywords
seq
human cytomegalovirus
sequences
variable region
neutralizing antibodies
Prior art date
Application number
PE2014000662A
Other languages
English (en)
Inventor
Antonio Lanzavecchia
Annalisa Macagno
Original Assignee
Inst Research In Biomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41550776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141432(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Research In Biomedicine filed Critical Inst Research In Biomedicine
Publication of PE20141432A1 publication Critical patent/PE20141432A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01D—HARVESTING; MOWING
    • A01D34/00—Mowers; Mowing apparatus of harvesters
    • A01D34/01—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus
    • A01D34/412—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters
    • A01D34/63—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters having cutters rotating about a vertical axis
    • A01D34/71—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters having cutters rotating about a vertical axis with means for discharging mown material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01D—HARVESTING; MOWING
    • A01D2101/00—Lawn-mowers
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01D—HARVESTING; MOWING
    • A01D34/00—Mowers; Mowing apparatus of harvesters
    • A01D34/01—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus
    • A01D34/412—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters
    • A01D34/63—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters having cutters rotating about a vertical axis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

SE REFIERE A UN ANTICUERPO HUMANO MONOCLONAL O UN FRAGMENTO DE UNION AL ANTIGENO QUE SE UNE AL CITOMEGALOVIRUS HUMANO (hCMV) QUE COMPRENDE: A) SECUENCIAS EN LA REGION VARIABLE DE LA CADENA PESADA CDR1, CDR2 Y CDR3 TAL COMO i) SEC ID N�: 145, 146 Y 147 RESPECTIVAMENTE, ii) SEC ID N�: 65, 66 Y 67 RESPECTIVAMENTE, iii) SEC ID N�: 129, 130 Y 131 RESPECTIVAMENTE, ENTRE OTROS; B) SECUENCIAS EN LA REGION VARIABLE DE LA CADENA LIVIANA CDR1, CDR2 Y CDR3 TAL COMO i) SEC ID N�: 148, 149 Y 150 RESPECTIVAMENTE, ii) SEC ID N�: 68, 69 Y 70 RESPECTIVAMENTE, iii) SEC ID N�: 132, 133 Y 134 RESPECTIVAMENTE, ENTRE OTROS; Y C) SECUENCIAS EN LA REGION VARIABLE DE LA CADENA PESADA Y LIVIANA DE i) SEC ID N� 157 Y 158 RESPECTIVAMENTE, ii) SEC ID N� 77 Y 78 RESPECTIVAMENTE, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE PUEDE CONTENER UN SEGUNDO ANTICUERPO. DICHO ANTICUERPO NEUTRALIZA LA INFECCION POR CITOMEGALOVIRUS HUMANO (hCMV)
PE2014000662A 2008-07-16 2009-07-15 Anticuerpos neutralizantes de citomegalovirus humano PE20141432A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8133408P 2008-07-16 2008-07-16

Publications (1)

Publication Number Publication Date
PE20141432A1 true PE20141432A1 (es) 2014-10-18

Family

ID=41550776

Family Applications (7)

Application Number Title Priority Date Filing Date
PE2014000667A PE20141435A1 (es) 2008-07-16 2009-07-15 Anticuerpos neutralizantes de citomegalovirus humano
PE2014000665A PE20141434A1 (es) 2008-07-16 2009-07-15 Anticuerpos neutralizantes de citomegalovirus humano
PE2014000662A PE20141432A1 (es) 2008-07-16 2009-07-15 Anticuerpos neutralizantes de citomegalovirus humano
PE2014000661A PE20141398A1 (es) 2008-07-16 2009-07-15 Anticuerpos neutralizantes de citomegalovirus humano
PE2014000664A PE20141433A1 (es) 2008-07-16 2009-07-15 Anticuerpos neutralizantes de citomegalovirus humano
PE2014000171A PE20140882A1 (es) 2008-07-16 2009-07-15 Anticuerpos neutralizantes de citomegalovirus humano
PE2011000035A PE20110413A1 (es) 2008-07-16 2009-07-15 Anticuerpos neutralizantes de la glicoproteina b de citomegalovirus humano

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2014000667A PE20141435A1 (es) 2008-07-16 2009-07-15 Anticuerpos neutralizantes de citomegalovirus humano
PE2014000665A PE20141434A1 (es) 2008-07-16 2009-07-15 Anticuerpos neutralizantes de citomegalovirus humano

Family Applications After (4)

Application Number Title Priority Date Filing Date
PE2014000661A PE20141398A1 (es) 2008-07-16 2009-07-15 Anticuerpos neutralizantes de citomegalovirus humano
PE2014000664A PE20141433A1 (es) 2008-07-16 2009-07-15 Anticuerpos neutralizantes de citomegalovirus humano
PE2014000171A PE20140882A1 (es) 2008-07-16 2009-07-15 Anticuerpos neutralizantes de citomegalovirus humano
PE2011000035A PE20110413A1 (es) 2008-07-16 2009-07-15 Anticuerpos neutralizantes de la glicoproteina b de citomegalovirus humano

Country Status (31)

Country Link
US (21) US8124093B2 (es)
EP (3) EP3009449B1 (es)
JP (5) JP5422649B2 (es)
KR (1) KR101356350B1 (es)
CN (3) CN103980363B (es)
AU (1) AU2009272284C1 (es)
BR (1) BRPI0916443A2 (es)
CA (2) CA3022196A1 (es)
CL (3) CL2011000084A1 (es)
CO (1) CO6351801A2 (es)
CR (2) CR20160355A (es)
CU (1) CU23953B1 (es)
DK (2) DK2352759T3 (es)
EA (1) EA031177B1 (es)
EC (2) ECSP11010826A (es)
ES (2) ES2654543T3 (es)
GT (4) GT201100011DA (es)
HK (1) HK1220981A1 (es)
HN (1) HN2011000161A (es)
IL (7) IL210356A (es)
MA (1) MA32561B1 (es)
MX (5) MX338067B (es)
NZ (5) NZ603499A (es)
PE (7) PE20141435A1 (es)
PH (1) PH12015500782A1 (es)
PL (2) PL2352759T3 (es)
PT (2) PT3009449T (es)
SG (3) SG191699A1 (es)
UA (1) UA106354C2 (es)
WO (1) WO2010007533A2 (es)
ZA (1) ZA201600335B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947274B2 (en) * 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
PT3009449T (pt) 2008-07-16 2018-09-28 Inst Res Biomedicine Anticorpos neutralizantes de citomegalovírus humano e utilização destes
JP5833565B2 (ja) 2009-12-23 2015-12-16 ４−アンティボディ・アクチェンゲゼルシャフト４−Ａｎｔｉｂｏｄｙ Ａｇ ヒトサイトメガロウイルスに対する結合メンバー
US9017668B2 (en) * 2010-06-16 2015-04-28 Trellis Bioscience, Llc High affinity human antibodies to human cytomegalovirus (CMV) gB protein
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
WO2012006369A2 (en) 2010-07-06 2012-01-12 Novartis Ag Immunisation of large mammals with low doses of rna
EP2590626B1 (en) 2010-07-06 2015-10-28 GlaxoSmithKline Biologicals SA Liposomes with lipids having an advantageous pka-value for rna delivery
PL2611461T3 (pl) 2010-08-31 2022-07-04 Glaxosmithkline Biologicals Sa Pegylowane liposomy do dostarczania rna kodującego immunogen
AU2011312425A1 (en) * 2010-09-29 2013-04-11 Genentech, Inc. Antibody compositions and methods of use
KR102266691B1 (ko) * 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
US11896636B2 (en) 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
EP2831119A1 (en) * 2012-03-28 2015-02-04 F. Hoffmann-La Roche AG Anti-hcmv idiotypic antibodies and uses thereof
JP6419695B2 (ja) 2012-07-27 2018-11-07 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ｕｌ１２８複合体の送達及びｃｍｖ感染の予防のためのｍｖａワクチン
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) * 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
JP6479660B2 (ja) 2012-08-24 2019-03-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン
US20170296650A1 (en) 2014-10-08 2017-10-19 Novartis Ag Combination of human cytomegalovirus neutralizing antibodies
EP3048114A1 (en) * 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
EP3991748A3 (en) 2015-04-07 2022-08-24 Alector LLC Anti-sortilin antibodies and methods of use thereof
EP3347045A4 (en) 2015-09-10 2019-08-28 City of Hope ANTIBODIES GENERATED BY MVA-GH / GL-PC VACCINE NEUTRALIZING THE INFECTIOUS POWER OF HUMAN CYTOMEGALOVIRUS AND ASSOCIATED METHODS
CN105296588A (zh) * 2015-10-16 2016-02-03 常州市第一人民医院 一种检测肾移植患者在术后感染巨细胞病毒危害程度的方法
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
EP3426676A1 (en) 2016-03-11 2019-01-16 Pfizer Inc Human cytomegalovirus gb polypeptide
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
SG10201913248VA (en) 2016-04-18 2020-02-27 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
CA3019588A1 (en) 2016-04-20 2017-10-26 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
EP3455251A4 (en) 2016-05-09 2020-04-22 Icahn School of Medicine at Mount Sinai WIDE NEUTRALIZING HUMAN ANTI-CYTOMEGALOVIRUS ANTIBODIES AND METHODS OF USE
WO2018005519A2 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
WO2018031903A1 (en) 2016-08-12 2018-02-15 Streck, Inc. Molecular reference controls
CN106519027B (zh) * 2016-11-11 2019-09-17 深圳先进技术研究院 抗h7n9全人源单克隆抗体5j13及其制法与应用
EP3609521A4 (en) * 2017-04-14 2021-06-16 University of Massachusetts TARGETING OF TROPISM CELL RECEPTORS TO INHIBIT CYTOMEGALOVIRUS INFECTION
WO2018193307A1 (en) 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
CN107325178A (zh) * 2017-06-29 2017-11-07 佛山市南海区普罗圣塔生物科技有限公司 一种抗人巨细胞病毒卵黄抗体及其制备方法和应用
WO2019183375A1 (en) * 2018-03-22 2019-09-26 Eureka Therapeutics, Inc. Antibody agents specifically recognizing monocarboxylate transporter 4 and uses thereof
US20210198374A1 (en) 2018-04-17 2021-07-01 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
PE20210186A1 (es) 2018-07-13 2021-02-02 Alector Llc Anticuerpos anti-sortilina y metodos para su uso
CA3116175A1 (en) 2018-10-17 2020-04-23 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
CN109580944A (zh) * 2018-12-07 2019-04-05 潍坊医学院 一种人巨细胞病毒检测试纸及其制造方法
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN109738631A (zh) * 2019-01-21 2019-05-10 潍坊医学院 一种人巨细胞病毒IgM抗体检测试纸的制备方法
WO2020176871A1 (en) * 2019-02-28 2020-09-03 Ann And Robert H. Lurie Children's Hospital Of Chicago Kawasaki disease antibodies identify hepacivirus peptides
WO2020208082A1 (en) * 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cmv related diseases
CN112898414A (zh) * 2019-12-04 2021-06-04 珠海泰诺麦博生物技术有限公司 抗人巨细胞病毒抗体及其用途
WO2021191836A1 (en) * 2020-03-27 2021-09-30 Glaxosmithkline Biologicals Sa Hcvm pentamer binding antibodies
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
WO2023034950A2 (en) * 2021-09-03 2023-03-09 Icahn School Of Medicine At Mount Sinai Anti-hcmv antibodies and antigen-binding fragments thereof
CN116162154A (zh) * 2022-10-21 2023-05-26 珠海泰诺麦博生物技术有限公司 抗人巨细胞病毒抗体及其用途
CN115947869B (zh) * 2022-11-28 2023-12-12 广州佰芮慷生物科技有限公司 一种靶向人巨细胞病毒的嵌合抗原受体、car-nk细胞及用途

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4294817A (en) 1977-11-25 1981-10-13 International Diagnostic Technology, Inc. Method of fluoro immunoassay
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4313927A (en) 1979-10-19 1982-02-02 Ames-Yissum Ltd. Immunoassay method for detecting viral antibodies in whole blood samples
US4334016A (en) 1980-06-19 1982-06-08 The Wistar Institute Of Anatomy And Biology Human osteogenic sarcoma cell line and use thereof for immunofluorescent antibody test
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
FR2543570B1 (fr) 1983-03-31 1985-08-09 Pasteur Institut Anticorps monoclonaux anticytomegalovirus humains, hybridomes secreteurs de ces anticorps et polypeptides porteurs d'un determinant antigenique sequentiel de cytomegalovirus humains
US4617379A (en) 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
GB8404368D0 (en) 1984-02-20 1984-03-28 Cogent Ltd Monoclonal antibodies to human cytomegalovirus
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
FR2563630B1 (fr) 1984-04-27 1988-02-19 Pasteur Institut Anticorps monoclonaux anticytomegalovirus et procedes pour le diagnostic in vitro des infections par les cytomegalovirus humains et d'une proteine-kinase inductible par les cytomegalovirus et susceptible d'etre reconnue par les susdits anticorps monoclonaux
US4783399A (en) 1984-05-04 1988-11-08 Scripps Clinic And Research Foundation Diagnostic system for the detection of cytomegalovirus
US4743562A (en) 1984-08-21 1988-05-10 The Board Of Trustees Of The Leland Stanford Junior University Purified human cytomegalovirus protein
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
DE3581400D1 (de) 1984-09-28 1991-02-21 Teijin Ltd Maus/mensch-hybridoma mit erzeugung von antiviralen menschlichen antikoerpern, deren herstellung und antivirale menschliche monoklonale antikoerper.
US4808518A (en) 1985-02-11 1989-02-28 University Of Tennessee Research Corporation Recovery of cytomegalovirus antigen and use thereof in an assay
US4804627A (en) 1985-05-09 1989-02-14 Sloan-Kettering Institute For Cancer Research Method for cloning lymphoblastoid cells
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1987003602A1 (en) 1985-12-06 1987-06-18 Teijin Limited Anticytomegaloviral human monoclonal antibody and process for its preparation
US6162620A (en) 1986-03-07 2000-12-19 Cogent Limited Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5126130A (en) 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
US5153311A (en) 1986-11-24 1992-10-06 The Children's Hospital, Incorporated Immunogenic glycoproteins of human cytomegalovirus gCII
LU86752A1 (fr) 1987-01-30 1988-08-23 Univ Bruxelles Procede de production d'anticorps monoclonaux humains(igg)anticytomegalovirus et anticorps monoclonaux ainsi obtenus
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
US5180813A (en) 1989-03-24 1993-01-19 University Of Iowa Research Foundation Early envelope glycoprotein of human cytomegalovirus (hmcv) and monoclonal antibodies to the glycoproteins
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
WO1991004277A1 (en) 1989-09-14 1991-04-04 Children's Biomedical Research Institute Monoclonal antibodies specific to cytomegalovirus glycoprotein
WO1991005876A1 (en) 1989-10-20 1991-05-02 Children's Biomedical Research Institute Human cytomegalovirus-specific monoclonal antibody cocktail
GB9008223D0 (en) 1990-04-11 1990-06-13 Royal Free Hosp School Med Improvements relating to the detection of viruses
DE4035174A1 (de) 1990-11-06 1992-05-07 Biotest Ag Verfahren zur bestimmung von proteinen in koerperfluessigkeiten und mittel zur durchfuehrung des verfahrens
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
JPH053794A (ja) 1991-06-26 1993-01-14 Green Cross Corp:The 抗サイトメガロウイルスヒトモノクローナル抗体およびその産生細胞
DE4128684A1 (de) 1991-08-29 1993-03-04 Behringwerke Ag Hcmv-spezifische peptide, mittel dazu und ihre verwendung
ATE173543T1 (de) 1992-04-10 1998-12-15 Thomas Totterman Verfahren zum nachweis einer cmv-infektion
SE9201281L (sv) 1992-04-23 1993-10-24 Bioinvent Int Ab Nya humana monoklonala antikroppar och förfarande för framställning därav
JPH05260961A (ja) 1992-05-21 1993-10-12 Teijin Ltd サイトメガロウイルスに対するヒト・モノクローナル抗体を産生するハイブリドーマ
GB9221654D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
AU681115B2 (en) 1993-01-21 1997-08-21 Erna Moller Prevention and treatment of cytomegalovirus using aminopeptidase
US5750106A (en) 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
JPH08506325A (ja) 1993-01-28 1996-07-09 サンド ファーマスーティカル コーポレーション サイトメガロウイルスに対するヒトモノクローナル抗体
AU6777594A (en) 1993-04-30 1994-11-21 Scripps Research Institute, The Human monoclonal antibodies to human cytomegalovirus, and methods therefor
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
EP0702083A3 (de) 1994-07-26 1997-01-15 Biotest Ag Polypeptide und Fusionsproteine bestehend aus dem UL 57 Leserahmen bzw. dem C-terminalen Bereich des Tegumentproteins pp150 aus HCMV, entsprechende Oligonucleotide und Nachweis reagentien
US5502652A (en) 1994-08-24 1996-03-26 Hoggatt; Austin C. Method and apparatus for measuring heat transfer in small diameter pipes using acoustic signals
US5783383A (en) 1995-05-23 1998-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of detecting cytomegalovirus (CMV)
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5800981A (en) 1996-02-22 1998-09-01 University Of Limburg Human cytomegalovirus antigen and its use
EP0960336B1 (en) 1996-07-12 2002-10-09 Organon Teknika B.V. Peptide reagent for the detection of human cytomegalovirus (cmv)
JP2000516617A (ja) 1996-08-14 2000-12-12 ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー アテローム性動脈硬化病変の出現を予防するか又は遅らせるための方法及び組成物
US7504493B2 (en) * 1997-01-23 2009-03-17 The John Hopkins University Characterization of the yeast transcriptome
WO1998033892A1 (en) 1997-01-30 1998-08-06 Cedars-Sinai Medical Center Establishment of hhv-8+ lymphoma cell line, virus produced, antibody, diagnostic method and kit for detecting hhv-8 infection
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
WO1998057993A1 (en) 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
EP0996730A1 (en) 1997-07-18 2000-05-03 Connaught Laboratories Limited Nucleic acid vaccines encoding g protein of respiratory syncytial virus
JP2002512003A (ja) 1997-11-14 2002-04-23 コノート ラボラトリーズ リミテッド パラミキソウイルスワクチンのためのアルファウイルスベクター
DE19756214C1 (de) 1997-12-17 1999-02-25 Biotest Ag Polypeptide mit Aminosäuresequenzen aus dem N-terminalen Bereich von gp116 und deren Verwendung bei der Diagnostik, Prophylaxe und Therapie
JP3764047B2 (ja) 1998-03-12 2006-04-05 ジェネンテック・インコーポレーテッド 網膜ニューロン死の防止及び眼病の治療方法
ES2212607T3 (es) 1998-06-29 2004-07-16 Wolfgang Bergter Medicamentos antivirales y antirretrovirales radioinmunologicos basados en emisores de rayos alfa y beta.
RU2133472C1 (ru) 1998-09-16 1999-07-20 Унитарное государственное Московское предприятие по производству бактерийных препаратов Способ диагностики активной стадии цитомегаловирусной инфекции человека
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
ATE488583T1 (de) 2001-02-21 2010-12-15 Wistar Inst Rekombinant vektor, der ein infektiöses humanes cytomegalovirus genom mit konserviertem wildtyp- charakteristika klinisher isolate enthält
ITMI20012160A1 (it) 2001-10-18 2003-04-18 Edoardo Marchisio Sistema immunoenzimatico per la caratterizzazione antigenica dell'infezione attiva da cytomegalovirus e cmv confirmation test
CN1188427C (zh) * 2001-12-07 2005-02-09 暨南大学 检测hcmv抗体的重组嵌合肽抗原及其产生方法
US6828113B2 (en) 2002-03-21 2004-12-07 Cornell Research Foundation, Inc. IgM antibodies to the 70 kDa heat shock protein as a marker for cytomegalovirus infection
CN1305905C (zh) 2002-03-22 2007-03-21 Aprogen株式会社 人源化抗体及其制备方法
CA2480811A1 (en) 2002-04-01 2003-10-16 Agensys, Inc. Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
DE10232322A1 (de) 2002-07-16 2004-07-29 Hahn, Gabriele, Dr. Viral kodierte CxC determinieren den Gewebetropismus von HCMV
TWI270088B (en) 2002-11-29 2007-01-01 Furukawa Electric Co Ltd Insulated wire and resin dispersion
RU2239453C2 (ru) 2002-12-03 2004-11-10 Федеральное государственное унитарное предприятие " Научно-производственное объединение по медицинским иммунобиологическим препаратам " Микроген" Препарат иммуноглобулина человека против цитомегаловируса и способ его получения
CN1445243A (zh) * 2002-12-13 2003-10-01 中国疾病控制中心病毒病预防控制所 抗人巨细胞病毒人源中和性基因工程Fab抗体
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
WO2004076645A2 (en) 2003-02-27 2004-09-10 University Of Massachusetts Compositions and methods for cytomegalovirus treatment
US20060216302A1 (en) 2003-02-28 2006-09-28 Robert Root-Bernstein Immunological markers
US7662381B2 (en) 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
CA2573090A1 (en) 2004-07-09 2006-01-19 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Differences in intestinal gene expression profiles
BE1016287A6 (nl) 2004-07-14 2006-07-04 Picanol Nv Gaapvormingsonderdeel voor een weefmachine en weefmachine.
WO2006056027A1 (en) 2004-11-29 2006-06-01 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
ES2371083T3 (es) 2004-12-21 2011-12-27 Medimmune Limited Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
ATE503770T1 (de) 2005-03-14 2011-04-15 Us Gov Health & Human Serv Humane monoklonale antikörper gegen hendra- und nipah-viren
NZ563639A (en) 2005-06-29 2009-12-24 Compumedics Ltd Sensor assembly with conductive bridge
JP5142458B2 (ja) * 2005-06-30 2013-02-13 キヤノン株式会社 標的物質捕捉分子、標的物質捕捉用の素子、これらを用いた標的物質検出用の装置及びキット、並びに、標的物質の検出方法
DK1974020T3 (da) 2005-12-16 2011-10-03 Ribovax Biotechnologies Sa Fremgangsmåde til at opnå immortaliserede antistofudskillende celler
JPWO2007094423A1 (ja) 2006-02-15 2009-07-09 株式会社イーベック ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分
JP5225266B2 (ja) 2006-05-19 2013-07-03 テバ ファーマシューティカル インダストリーズ リミティド 融合タンパク質、その使用、およびその製造方法
CA2654563A1 (en) * 2006-06-07 2007-12-21 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
KR20090114364A (ko) 2006-12-15 2009-11-03 리보박스 바이오테크놀로지즈 에스아 인간 거대세포바이러스(에이치씨엠브이)에 대한 항체
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
WO2008120203A2 (en) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases
US20080248042A1 (en) 2007-04-05 2008-10-09 Irccs Centro Di Riferimento Oncologico Di Aviano, Monoclonal antibody cross-reactive against infective agent causing a B-cell expansion and IgG-Fc
EP2190876A1 (en) 2007-08-22 2010-06-02 Ribovax Biotechnologies SA Antibodies against human cytomegalovirus (hcmv)
US7763261B2 (en) 2007-12-19 2010-07-27 Dcb-Usa Llc Anti-human cytomegalovirus antibodies
WO2010000020A1 (en) 2008-06-30 2010-01-07 Cathrx Ltd A catheter
PT2303923E (pt) 2008-07-16 2015-08-25 Inst Research In Biomedicine Anticorpos neutralizantes de citomegalovírus humano e sua utilização
PT3009449T (pt) 2008-07-16 2018-09-28 Inst Res Biomedicine Anticorpos neutralizantes de citomegalovírus humano e utilização destes

Also Published As

Publication number Publication date
NZ603498A (en) 2014-02-28
US20170081391A1 (en) 2017-03-23
MX343490B (es) 2016-11-08
JP6062477B2 (ja) 2017-01-18
US8603480B2 (en) 2013-12-10
US20120128692A1 (en) 2012-05-24
EP3009449A1 (en) 2016-04-20
US9127049B2 (en) 2015-09-08
NZ591056A (en) 2013-02-22
JP2014087337A (ja) 2014-05-15
UA106354C2 (ru) 2014-08-26
US20170129939A1 (en) 2017-05-11
IL232861A (en) 2016-06-30
US9491906B2 (en) 2016-11-15
NZ707788A (en) 2016-08-26
IL232865A (en) 2016-07-31
IL238421A (en) 2016-06-30
US20130302350A1 (en) 2013-11-14
SG10201706350PA (en) 2017-09-28
MX338067B (es) 2016-04-01
EP3178845A1 (en) 2017-06-14
KR20110052585A (ko) 2011-05-18
EP2352759A2 (en) 2011-08-10
GT201100011CA (es) 2017-09-14
CR20110091A (es) 2011-06-24
GT201100011AA (es) 2017-09-14
CU20110009A7 (es) 2012-06-21
JP2011527902A (ja) 2011-11-10
US9796772B2 (en) 2017-10-24
US9371372B2 (en) 2016-06-21
HK1220981A1 (zh) 2017-05-19
ECSP11010826A (es) 2011-07-29
CN106924729B (zh) 2021-03-02
US20100092481A1 (en) 2010-04-15
ES2654543T3 (es) 2018-02-14
IL232863A0 (en) 2014-07-31
MX340315B (es) 2016-07-06
PE20141433A1 (es) 2014-10-19
US8435524B2 (en) 2013-05-07
IL232862A0 (en) 2014-07-31
AU2009272284B2 (en) 2012-04-05
US9249213B2 (en) 2016-02-02
US10414817B2 (en) 2019-09-17
EP2352759B1 (en) 2017-11-01
IL232862A (en) 2016-06-30
MX343250B (es) 2016-10-31
AU2009272284C1 (en) 2014-05-15
US20120128691A1 (en) 2012-05-24
US8287870B2 (en) 2012-10-16
US20130022618A1 (en) 2013-01-24
PE20141434A1 (es) 2014-10-22
JP2015145412A (ja) 2015-08-13
US20140193428A1 (en) 2014-07-10
CL2011000084A1 (es) 2011-07-01
MX2011000543A (es) 2011-04-27
WO2010007533A9 (en) 2017-08-10
CA2730776A1 (en) 2010-01-21
JP6345753B2 (ja) 2018-06-20
CL2014001293A1 (es) 2014-12-05
IL232863A (en) 2016-06-30
NZ603499A (en) 2014-05-30
SG10201608381SA (en) 2016-11-29
DK2352759T3 (en) 2017-12-18
JP5422649B2 (ja) 2014-02-19
US9221897B2 (en) 2015-12-29
KR101356350B1 (ko) 2014-01-27
CN102203133A (zh) 2011-09-28
SG191699A1 (en) 2013-07-31
US20180371062A1 (en) 2018-12-27
GT201100011DA (es) 2017-09-20
JP2018139611A (ja) 2018-09-13
IL232864A0 (en) 2014-07-31
HN2011000161A (es) 2014-06-09
US20210087257A1 (en) 2021-03-25
US9803000B1 (en) 2017-10-31
US9365636B1 (en) 2016-06-14
US20160280769A1 (en) 2016-09-29
PH12015500782A1 (en) 2015-12-14
IL210356A (en) 2015-06-30
BRPI0916443A2 (pt) 2017-10-31
IL232861A0 (en) 2014-07-31
AU2009272284A1 (en) 2010-01-21
PE20141435A1 (es) 2014-10-22
US20160280770A1 (en) 2016-09-29
US20170129940A1 (en) 2017-05-11
US20160145319A1 (en) 2016-05-26
CL2016001340A1 (es) 2016-10-28
US8298539B2 (en) 2012-10-30
CA2730776C (en) 2018-12-11
US20160096880A1 (en) 2016-04-07
CN103980363A (zh) 2014-08-13
US20200017575A1 (en) 2020-01-16
IL238421A0 (en) 2015-06-30
PL3009449T3 (pl) 2018-09-28
US10889632B2 (en) 2021-01-12
US9725502B2 (en) 2017-08-08
CR20160355A (es) 2016-10-11
US20170334972A1 (en) 2017-11-23
WO2010007533A3 (en) 2010-08-12
EP3009449B1 (en) 2018-06-06
US8124093B2 (en) 2012-02-28
US10040845B2 (en) 2018-08-07
PT3009449T (pt) 2018-09-28
EA031177B1 (ru) 2018-11-30
US8765132B2 (en) 2014-07-01
JP5807050B2 (ja) 2015-11-10
US20110268746A1 (en) 2011-11-03
IL232864A (en) 2016-07-31
CO6351801A2 (es) 2011-12-20
CA3022196A1 (en) 2010-01-21
PL2352759T3 (pl) 2018-04-30
US20150353627A1 (en) 2015-12-10
ECSP11010827A (es) 2011-07-29
PE20140882A1 (es) 2014-07-25
DK3009449T3 (en) 2018-08-06
US20140205615A1 (en) 2014-07-24
US20180086819A1 (en) 2018-03-29
CU23953B1 (es) 2013-10-29
JP2017055765A (ja) 2017-03-23
CN103980363B (zh) 2017-04-12
NZ619953A (en) 2015-06-26
CN102203133B (zh) 2015-01-07
PT2352759T (pt) 2018-01-08
US9796771B2 (en) 2017-10-24
PE20141398A1 (es) 2014-10-18
EA201170205A1 (ru) 2011-08-30
PE20110413A1 (es) 2011-06-25
CN106924729A (zh) 2017-07-07
WO2010007533A2 (en) 2010-01-21
GT201100011BA (es) 2017-09-14
ZA201600335B (en) 2017-11-29
JP6703037B2 (ja) 2020-06-03
ES2682596T3 (es) 2018-09-21
IL210356A0 (en) 2011-03-31
US9527902B2 (en) 2016-12-27
MA32561B1 (fr) 2011-08-01
IL232865A0 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
PE20141432A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20120079A1 (es) Moleculas de anticuerpos mejoradas
PE20120306A1 (es) Anticuerpos anti-egfr y vectores que los codifican
PE20130393A1 (es) Anticuerpos con union de antigenos dependiente de ph
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
PE20121649A1 (es) Anticuerpos monoclonales frente a progastrina y sus usos
RS54393B1 (en) HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR
PE20121552A1 (es) Anticuerpos monoclonales anti cea humanizados de afinidad madura
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20121023A1 (es) Anticuerpos e inmunoconjugados
PE20120816A1 (es) Composiciones que comprenden anticuerpos de dickkopf-1
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
PE20131209A1 (es) Anticuerpos anti-fap
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
RU2010133547A (ru) Анти-cldn антитела
PE20160553A1 (es) Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7
ES2570153T3 (es) Anticuerpos anti-C5aR con propiedades mejoradas
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
PE20121579A1 (es) Proteinas de enlace al antigeno il-23 humanas
PE20142407A1 (es) Formulacion de anticuerpos
PE20140247A1 (es) Anticuerpos anti-cd38
UY30260A1 (es) Anticuerpos dirigidos contra upar y usos de los mismos
PE20081478A1 (es) Anticuerpos cd44

Legal Events

Date Code Title Description
FD Application declared void or lapsed